The biosynthesis of acarbose and validamycin

Area of Science:

• Biochemistry
• Metabolic pathways
• Carbohydrate chemistry

Background:

• Acarbose and validamycin are important pharmaceuticals with complex pseudodisaccharide structures.
• Understanding their biosynthesis is crucial for potential drug development and metabolic engineering.
• Previous studies have hinted at shared origins but differing pathways for their core components.

Purpose of the Study:

• To elucidate the complete biosynthetic pathways of acarbose and validamycin.
• To identify key intermediates and enzymes involved in their formation.
• To compare and contrast the distinct routes leading to these related compounds.

Main Methods:

• Isotopic labeling studies to trace metabolic origins.
• Enzymatic assays to identify key catalytic steps.
• Structural analysis of intermediates and final products.

Main Results:

• The mC7N units of acarbose and validamycin originate from sedo-heptulose 7-phosphate.
• 2-epi-5-epi-valiolone is the initial cyclization product for both compounds.
• The deoxyhexose moiety of acarbose derives from glucose via dTDP-4-keto-6-deoxy-D-glucose.
• Validamycin A biosynthesis involves distinct ketocyclitol intermediates (5-epi-valiolone, valienone, validone).
• No free intermediates were identified between 2-epi-5-epi-valiolone and the acarbose pseudodisaccharide.

Conclusions:

• The biosynthetic pathways for acarbose and validamycin, despite a common precursor for their aminocyclitol moieties, are substantially different.
• The identification of specific intermediates highlights the unique enzymatic machinery involved in each pathway.
• Further research is needed to uncover the mechanism of the nitrogen bridge formation connecting the pseudodisaccharide components.